Sitagliptin improves plasma apolipoprotein profile in type 2 diabetes : A randomized clinical trial of sitagliptin effect on lipid and glucose metabolism (SLIM) study
(2020) In Diabetes Research and Clinical Practice 162. p.1-9- Abstract
AIM: This study aims to evaluate the effect of dipeptidyl peptidase-4 inhibitors on lipid metabolism in patients with type 2 diabetes mellitus (T2D).
METHODS: This is a multicenter, open-labeled, randomized controlled study. T2D patients with HbA1c 6.9-8.9% (52-74 mmol/mol) who were under treatment with sulfonylurea were randomly allocated to either the sitagliptin group or the non-sitagliptin group. Glucose and lipid metabolism parameters including apolipoproteins (apo), sterols, and urinary albumin were assessed at baseline, 3, and 6 months of the treatment.
RESULTS: A total of 164 patients completed the 6-month observation (n = 81 for sitagliptin and n = 83 for non-sitagliptin). HbA1c decreased in the sitagliptin group... (More)
AIM: This study aims to evaluate the effect of dipeptidyl peptidase-4 inhibitors on lipid metabolism in patients with type 2 diabetes mellitus (T2D).
METHODS: This is a multicenter, open-labeled, randomized controlled study. T2D patients with HbA1c 6.9-8.9% (52-74 mmol/mol) who were under treatment with sulfonylurea were randomly allocated to either the sitagliptin group or the non-sitagliptin group. Glucose and lipid metabolism parameters including apolipoproteins (apo), sterols, and urinary albumin were assessed at baseline, 3, and 6 months of the treatment.
RESULTS: A total of 164 patients completed the 6-month observation (n = 81 for sitagliptin and n = 83 for non-sitagliptin). HbA1c decreased in the sitagliptin group but not in the non-sitagliptin group. Serum TG and total, LDL and HDL cholesterol levels did not change in either group. Apo B-48, apo CII, and apo CIII levels decreased in the sitagliptin group, but not in the non-sitagliptin group. The change in urinary albumin was significantly different between the groups with a preferable change in the sitagliptin group. There were no changes in serum sterols levels in the two groups.
CONCLUSIONS: The treatment of sitagliptin for 6 months improves the metabolism of glucose and chylomicron and reduces plasma levels of atherogenic lipoproteins in patients with T2D.
(Less)
- author
- Tanimura-Inagaki, Kyoko ; Nagao, Mototsugu LU ; Harada, Taro ; Sugihara, Hitoshi ; Moritani, Shigeki ; Sasaki, Jun ; Kono, Suminori and Oikawa, Shinichi
- author collaboration
- publishing date
- 2020-04
- type
- Contribution to journal
- publication status
- published
- keywords
- Apolipoproteins/drug effects, Diabetes Mellitus, Type 2/blood, Dipeptidyl-Peptidase IV Inhibitors/therapeutic use, Female, Glucose/metabolism, Humans, Hypoglycemic Agents/pharmacology, Lipids/blood, Male, Middle Aged, Sitagliptin Phosphate/pharmacology, Sulfonylurea Compounds/therapeutic use
- in
- Diabetes Research and Clinical Practice
- volume
- 162
- article number
- 108119
- pages
- 1 - 9
- publisher
- Elsevier
- external identifiers
-
- scopus:85082725754
- pmid:32194219
- ISSN
- 1872-8227
- DOI
- 10.1016/j.diabres.2020.108119
- language
- English
- LU publication?
- no
- additional info
- Copyright © 2020. Published by Elsevier B.V.
- id
- ea21dd75-67cb-4ef2-a8ec-ed31d495e017
- date added to LUP
- 2023-01-12 01:50:04
- date last changed
- 2024-04-29 02:11:25
@article{ea21dd75-67cb-4ef2-a8ec-ed31d495e017,
abstract = {{<p>AIM: This study aims to evaluate the effect of dipeptidyl peptidase-4 inhibitors on lipid metabolism in patients with type 2 diabetes mellitus (T2D).</p><p>METHODS: This is a multicenter, open-labeled, randomized controlled study. T2D patients with HbA1c 6.9-8.9% (52-74 mmol/mol) who were under treatment with sulfonylurea were randomly allocated to either the sitagliptin group or the non-sitagliptin group. Glucose and lipid metabolism parameters including apolipoproteins (apo), sterols, and urinary albumin were assessed at baseline, 3, and 6 months of the treatment.</p><p>RESULTS: A total of 164 patients completed the 6-month observation (n = 81 for sitagliptin and n = 83 for non-sitagliptin). HbA1c decreased in the sitagliptin group but not in the non-sitagliptin group. Serum TG and total, LDL and HDL cholesterol levels did not change in either group. Apo B-48, apo CII, and apo CIII levels decreased in the sitagliptin group, but not in the non-sitagliptin group. The change in urinary albumin was significantly different between the groups with a preferable change in the sitagliptin group. There were no changes in serum sterols levels in the two groups.</p><p>CONCLUSIONS: The treatment of sitagliptin for 6 months improves the metabolism of glucose and chylomicron and reduces plasma levels of atherogenic lipoproteins in patients with T2D.</p>}},
author = {{Tanimura-Inagaki, Kyoko and Nagao, Mototsugu and Harada, Taro and Sugihara, Hitoshi and Moritani, Shigeki and Sasaki, Jun and Kono, Suminori and Oikawa, Shinichi}},
issn = {{1872-8227}},
keywords = {{Apolipoproteins/drug effects; Diabetes Mellitus, Type 2/blood; Dipeptidyl-Peptidase IV Inhibitors/therapeutic use; Female; Glucose/metabolism; Humans; Hypoglycemic Agents/pharmacology; Lipids/blood; Male; Middle Aged; Sitagliptin Phosphate/pharmacology; Sulfonylurea Compounds/therapeutic use}},
language = {{eng}},
pages = {{1--9}},
publisher = {{Elsevier}},
series = {{Diabetes Research and Clinical Practice}},
title = {{Sitagliptin improves plasma apolipoprotein profile in type 2 diabetes : A randomized clinical trial of sitagliptin effect on lipid and glucose metabolism (SLIM) study}},
url = {{http://dx.doi.org/10.1016/j.diabres.2020.108119}},
doi = {{10.1016/j.diabres.2020.108119}},
volume = {{162}},
year = {{2020}},
}